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Abstract      
Management of uncomplicated malaria worldwide is threatened by the emergence in Asia of 
Plasmodium falciparum carrying variants of the pfk13 locus and exhibiting reduced susceptibility to 
artemisinin. Mutations in two other genes, ubp1 and ap2, are associated with artemisinin resistance 
in rodent malaria and with clinical failure of combination therapy in African malaria patients.  
Transgenic P. falciparum clones, each carrying orthologues of mutations in pfap2and pfubp1 
associated with artemisinin resistance in P. chabaudi, were derived by Cas9 gene editing. 
Susceptibility to artemisinin and other antimalarial drugs was determined.  
Following exposure to 700 nM dihydroartemisinin in the ring-stage survival assay we found strong 
evidence that transgenic parasites expressing the I592T variant (11% survival), but not the S160N 
variant (1% survival), of the AP2 adaptin subunit were significantly less susceptible than were the 
parental wild-type parasite population. The V3275F variant of UBP1, but not the V3306F variant, also 
displayed reduced susceptibility to dihydroartemisinin (8.5% survival vs 0.5% survival). AP2 and 
UBP1 variants did not elicit reduced susceptibility to 48 hours of artemisinin exposure, or to other 
antimalarial drugs. Therefore, variants of the AP2 adaptor complex -subunit and of the ubiquitin 
hydrolase UBP1 reduce in vitro artemisinin susceptibility at the early ring-stage in P. falciparum. 
These findings confirm the existence of multiple pathways to perturbation of either the mode of action 
of artemisinin, the parasite’s adaptive mechanisms of resistance, or both. The cellular role of UBP1 
and AP2 in Plasmodium parasites should now be elucidated.  
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Introduction   
Artemisinin combination therapies (ACT) remain the recommended treatment for uncomplicated P. 
falciparum worldwide.1 Although ACT are still broadly effective in Sub-Saharan Africa, reduced 
susceptibility to artemisinin and the partner drug piperaquine has been demonstrated throughout the 
Greater Mekong subregion, and there is some evidence of decreasing effectiveness in Africa.2-9 
Reduced susceptibility to artemisinin in Southeast Asia has been linked to particular mutations in the 
propeller domain of the pfkelch13 (K13) gene. 2,3 However, these mutations are not widely observed 
in other regions, and the distinct K13 mutations identified at low frequency in Africa do not correlate 
with either delayed clearance or parasite recrudescence in field studies and travellers. 6,8,9 Reduced 
artemisinin susceptibility in vitro can be generated experimentally by the introduction of variant K13 
genes into transgenic parasite lines, 10 but understanding of other genetic determinants of artemisinin 
and partner drug failure is critical to preserving ACT efficacy worldwide.  
In 2007, Hunt et al evolved artemisinin-resistant lines of the rodent malaria P. chabaudi in vivo and 
described mutations associated with the phenotype by linkage analysis. 11 These included variants of 
pcubp1, encoding a putative ubiquitin hydrolase, and pcap2 encoding the  subunit of the AP2 
vesicular trafficking complex. 11,12 Subsequent gene sequencing of peripheral blood parasites from 
Kenyan patients revealed that the Ser160Asn mutation in the P. falciparum homologue of this gene, 
pfap2, was associated with ACT treatment failure and that certain alleles of pfubp1 were also more 
common among parasites surviving treatment. 13 Similar alleles of pfubp1 had been previously 
identified in studies of in vitro artemisinin susceptibility of cultured Kenyan isolates of P. 
falciparum.14 We generated transgenic parasites in vitro that harboured an additional, constitutively 
expressed  copy of the modified locus PfAP2µSer160Asn, a genotype which currently circulates across 
Africa.8,13 Some evidence was found of altered susceptibility to artemisinin and other frontline 
chemotherapies in these lines, in which the endogenous wild-type locus was also present and active.15 
The availability of genome editing systems in Plasmodium falciparum now provides an opportunity to 
perform gene replacement of the endogenous loci of interest to more directly test the impacts of 
pfap2µ and pfubp1 mutations on parasite drug susceptibility. 10  
In this study, we used Cas9 editing to generate parasites harbouring the PfAP2Ile592Thr 
orthologue of the PcAP2Ile568Thr P. chabaudi mutation,12 and the PfAP2Ser160Asn variant seen in 
Africa.13 We also introduced into the pfubp1 locus, separately, sequences encoding the Val3275Phe 
and Val3306Phe variants, corresponding to P. chabaudi mutations previously described by Hunt et 
al.11 The in vitro susceptibility to artemisinin and other frontline antimalarials of these gene-edited 
parasites was determined and compared to previously validated ART-R P. falciparum isolates of 
Cambodian origin expressing K13 variants.  
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MATERIALS & METHODS: 
Plasmid Design and Construction 
Plasmids pL6-AP2µIle592Thr-sgDNA and pL6-AP2µIle592Ile-sgDNA, including a recodonised donor 
sequence carrying the mutation of interest, were constructed as described.16 Constructs to install the 
pfap2µSer160Asn, pfubp1Val3275Phe, and pfubp1Val3306Phe mutations were similarly designed (Supplemental 
Data).  
Parasite Lines  
Plasmid constructs were transfected into laboratory clone 3D7. Cambodian origin lines Cam3.IIR539T, 
Cam3.IIC580Y and Cam3.IIREV were kindly provided by the laboratory of David Fidock. 10 All Cam3.II-
lineage parasites harbour wild-type pfap2µ and pfubp1 alleles.  
Parasite Culture and Generation of transgenic parasites 
Plasmodium falciparum culture was performed in A+ erythrocytes obtained from the UK Blood Bank. 
Parasites were cultured in RPMI supplemented with Albumax II, L-glutamine, and gentamycin, at 5% 
haematocrit under 5% CO2 conditions at 37ºC. Parasites were synchronised using 70% Percoll 
gradients to capture schizonts and 5% sorbitol to isolate ring-stage parasites.  
For transfection, 3D7 parasites were cultured to approximately 10-15% ring-stage parasitaemia at 5% 
haematocrit under standard conditions. Immediately before transfection, 100 µg of each plasmid was 
resuspended in 100 µl of sterile TE buffer. 250 µl packed cells equilibrated in 1 x Cytomix (120 mM 
KCl, 5 mM MgCl2, 25 mM HEPES, 0.15 mM CaCl2, 2 mM EGTA, 10 mM KH2PO4/K2HPO4, pH 
7.6) was combined with 250 µl of 1 x Cytomix in a 2 mm transfection cuvette (Bio-Rad Laboratories) 
and plasmid DNA was added. The cells were pulsed at 310V, 950 µF, and infinite resistance in a Bio-
Rad Gene Pulser, washed and returned to culture. Fresh erythrocytes were added to approximately 5% 
total haematocrit on day 1 after transfection along with 2.5 nM WR99210 and 1.5 µM DSM-1. Media 
and selection drugs were replenished every day for 14 days and then every 3 days until parasites were 
observed by microscopy. Parasites recovered to microscopically detectable levels approximately 3 
weeks post-transfection, and genotype was confirmed by PCR-RFLP mapping and Sanger 
sequencing. In particular, the donor template for installing pfap2µ(I592T) introduced a silent SpeI 
restriction site, and the template for installing pfap2µ(S160N) silently ablated an endogenous SnaBI 
restriction site. Both donor templates for pfubp1 mutations introduced HindIII restriction sites. 
Parasites were cloned by limiting dilution, whereby cultures were seeded at 0.3 parasites/well in 250 
µl of 2% haematocrit culture in a 96-well plate. Spent media was removed and replaced with 
complete media supplemented with 0.5% (v/v) fresh red blood cells weekly for three weeks. Parasite 
growth was examined after three weeks by LDH assay and microscopy, and several clones were 
selected for genotype confirmation and further characterisation. Approximately one third of each 
cloning plate contained parasites, consistent with the seeding parasite density.  
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In vitro Drug Susceptibility Assays  
Synchronised ring stage parasites at 0.5% parasitaemia and 2% haematocrit were exposed to 
dihydroartemisinin (DHA), quinine, chloroquine, lumefantrine, piperaquine, and mefloquine over a 
full 48 h lifecycle in two biological replicates in a 96-well array bearing serial two-fold drug dilutions. 
The plate was incubated at 37°C for 48 hours and EC50 estimates determined as described.17 RSA0-4h 
experiments were carried out exactly as described. 18 FACS was performed on live cells stained with 
1:10,000 MitoTracker Deep Red and 1:1,000 SYBR Green (Invitrogen Molecular Probes) in PBS for 
20 minutes at 37°C. Cells were stained using 8 volumes of stain solution per volume of culture (2% 
haematocrit) and analysed using a LSR-II Flow Cytometer (BD Biosciences).  Statistical comparisons 
of drug susceptibility were by the non-parametric Mann Whitney U test.   
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RESULTS: 
AP2 modifications alter in vitro susceptibility to frontline chemotherapies  
The orthologue of the P. chabaudi AP2µIle568Thr variant, 11 PfAP2µIle592Thr, was efficiently installed by 
CRISPR-Cas9 editing onto the P. falciparum 3D7 background. In parallel, a PfAP2µIle592Ile transgenic 
line expressing the wild-type Ile592 codon in the context of recodonisation ablating the Cas9 PAM 
site was also generated (Fig. 1A, 1B; left panels) to rule out a role for silent mutations in drug 
susceptibility. Both lineages were cloned by limiting dilution, and susceptibility profiles of two clones 
of each lineage to chloroquine, quinine, DHA, lumefantrine, piperaquine, and mefloquine were 
characterised. While there was no difference between mutant and wild-type parasites in susceptibility 
to a 48 h exposure to DHA, quinine, piperaquine, or mefloquine, the 592Thr parasites were more 
susceptible to lumefantrine (592Thr: 21.3 nM, Ile592: 30.83 nM; mean diff 9.15 nM; P = 0.0067) and 
chloroquine (592Thr: 8.05 nM, Ile592: 11.88 nM; mean diff 3.83 nM; P < 0.0001) (Table 1). No 
effect on intra-erythrocytic growth was seen with the Ile592Thr transgenic lines (Suppl. Fig. 1).  
We then characterised the susceptibility of these clones to artemisinin using the ring stage survival 
assay (RSA), 2,18 an in vitro correlate of in vivo parasite susceptibility in which early ring stage 
parasites are exposed to a brief pulse of 700 nM DHA. Artemisinin susceptibility was also determined 
for three Cam3.II-derived Cambodian parasite lines, 10 and the parental 3D7 line, as validated 
controls. Both clones encoding the PfAP2µIle592Thr variant displayed higher ring stage survival rates 
(clone 1: 11.2%; clone 2: 9.3% survival) than the parental 3D7 strain (1.3% survival). Silent 
recodonisation had no effect on artemisinin susceptibility, as both gene-edited Ile592Ile clones 
displayed equivalent artemisinin susceptibility to 3D7 (Fig. 2). For comparison, the Cam3.II 
Cambodian clinical isolate harbouring the PfK13Arg539Thr variant, and a derived gene-edited line 
harbouring PfK13Cys580Tyr displayed significantly enhanced survival in the RSA of 28.0% and 17.3%, 
respectively, when compared to a gene-edited Cam3.II line expressing wild-type K13 (Cam3.IIREV: 
2.63% survival).  
Clones of a lineage expressing PfAP2µSer160Asn (Fig. 1A, 1B; right panels), which currently circulates 
in Africa and was previously associated with delayed parasite clearance in clinical studies, did not 
show enhanced survival in this assay (Fig. 2). This mutant allele also had no effect on 48 h 
susceptibility to any of the drugs examined (Table 1). These data confirm that a single amino acid 
change in AP2µ at codon 592 can confer significantly increased ring-stage survival on an otherwise 
artemisinin-susceptible genetic background.  
The Val3275Phe variant of PfUBP1 reduces ring-stage artemisinin susceptibility in vitro 
To evaluate the impacts of UBP1 mutation on parasite susceptibility to artemisinin and other frontline 
chemotherapies, we used Cas9 editing to generate two P. falciparum lineages expressing orthologues 
of the original P. chabaudi mutations, encoding PfUBP1Val3275Phe and PfUBP1Val3306Phe (Fig. 3). The 
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donor templates and sgRNA Cas9 guide sequences used to generate each mutation were identical 
except for these point mutations. Three weeks after transfection and selection, transgenic parasites 
were obtained, cloned by limiting dilution, and genotyped by PCR-RFLP and Sanger sequencing.  
Two clones of each parasite lineage were examined for their susceptibility to 48 h exposures to 
dihydroartemisinin, chloroquine, quinine and piperaquine (Table 2). There were no differences in 
EC50 estimates for any chemotherapy between either clone of 3D7-UBP1Val3275Phe and 3D7. Both 
clones of 3D7-UBP1Val3306Phe were more sensitive than 3D7 to chloroquine. There were no differences 
in EC50 estimates for each drug between the clones of each mutant lineage.  
We then examined both clones of each of the pfubp1 mutant lineages for ring-stage susceptibility to 
dihydroartemisinin in the RSA (Figure 4). Parasites expressing UBP1Val3275Phe displayed a more than 
five-fold increase in ring-stage survival compared to wild type 3D7 progenitors (clone 1: 6.46%, 
clone 2: 6.54%; 3D7: 1.2%; P < 0.005). The two Val3306Phe clones displayed equivalent sensitivity 
to 3D7 (clone 1: 1.46%; clone 2: 1.96%; P > 0.05). There was no difference in survival between the 
two clones within each mutant lineage, and no effect on intra-erythrocytic growth was seen (Suppl. 
Fig. 1).   
 
  
8 
 
DISCUSSION  
In this study we present evidence that mutations in genes encoding the  subunit of the AP2 
trafficking complex and the ubiquitin hydrolase UBP1 can generate reduced P. falciparum ring-stage 
artemisinin susceptibility in vitro similar to that characteristic of K13-mediated ART-R circulating in 
the Greater Mekong Subregion. 10 These susceptibility phenotypes are also similar to those seen in the 
recently described laboratory-evolved parasites of Senegalese origin harbouring PfCoronin variants. 19 
Thus, reduced in vitro ring-stage susceptibility due to a single amino acid substitution has now been 
demonstrated for four loci, including pfk13.  
Resistance to artemisinin has long been proposed to be multigenic. So far, laboratory evolution of 
reduced artemisinin susceptibility has failed to generate parasites with the most prevalent K13 
mutations seen in the field, confirming the importance of examining parasite genetic background 
when considering drug resistance in the clinic. Resistant variants in K13 only occur naturally in the 
presence of variants of certain other proteins, perhaps compensating for loss of fitness due to the 
primary change, 20,21 and this is supported by the results of a recent genetic cross of parasites 
harbouring pfk13 C580Y with pfk13 wild-type parasites. 22 Although pfk13 genotype at codon 580 
determined whether RSA survival was high or low among the progeny, variation within these two 
groups was modulated by other heritable variant loci. Previous work has implicated intracellular 
trafficking and protein turnover in the mechanism of artemisinin resistance, 23 and our work here 
provides further support for these conclusions. In nearly all other systems, the AP2 trafficking 
complex mediates endocytosis from the plasma membrane, and deubiquitinases are often involved in 
protein degradation and recycling. A functional characterisation of both proteins is needed to resolve 
the broader mechanisms underlying this complicated phenotype.  
Our findings clarify that the PfAP2µSer160Asn mutation has no effect on ring-stage artemisinin 
susceptibility. Our previous conclusions suggested a possible increase in DHA 48 h-EC50 when 
overexpressing Ser160Asn in a multidrug-resistant background (the Dd2 parasite line from Southeast 
Asia).15 However, even though this work was performed before the standardisation of the RSA, we 
found no evidence of increased survival to a ring-stage artemisinin pulse at that time. Here, using the 
RSA and 48 h EC50 assay formats, we also failed to detect any reduced artemisinin susceptibility 
mediated by this mutation in a chloroquine-sensitive parasite background (3D7). Further Cas9-editing 
experiments should be done in the CQ-resistant Dd2 background, but our results to date suggest that 
Ser160Asn is insufficient to generate reduced artemisinin susceptibility alone, and thus any 
correlation with ACT failure observed in human infections 8, 13, 15 is due to either other benefits of the 
genotype, or linkage with other genetic factors. Nevertheless, our RSA results from the Ile592Thr 
mutant clearly indicate that AP2µ variants can elicit reduced ring-stage parasite susceptibility to 
artemisinin.   
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Our data also confirm the ability of variants of UBP1 to mediate reduced artemisinin susceptibility. 
We examined the UBP1 and AP2µ mutations identified in P. chabaudi in isolation to understand their 
individual contributions to artemisinin sensitivity. In the rodent model, the orthologue of 
PfUBP1Val3306Phe co-occurred with the orthologue of PfAP2µIle592Thr, whereas the latter arose 
specifically during artemisinin pressure.11 Consistent with this, in our hands, PfUBP1Val3306Phe is 
insufficient to generate artemisinin resistance. An obvious next experiment is to examine the effects 
of these mutations together in a single lineage. Interestingly, neither pfubp1 mutation conferred any 
protection from chloroquine, as the rodent model might suggest. However, careful analysis of the 
linkage data from the seminal experiments of Hunt et al. revealed that pcubp1 mutations were only 
associated with CQ-R in the context of another mutation in pcaat1, an amino acid transporter.11 As 
with AP2µ, exploring these combinatorial effects on drug susceptibility in P. falciparum will form the 
basis for important future studies.  
The RSA as an in vitro test of artemisinin susceptibility phenotype is only a few years old and has 
been developed in parallel in different labs since it was first described. 24 Inter-lab variability has not 
as yet been explored with any rigour, but as an initial approach to ensuring comparability between 
among obtained from different research teams, the inclusion of common control parasite lines is an 
important step towards standardisation. We were able to use the Cam3.II series of P. falciparum lines 
engineered in the Fidock laboratory as controls in our RSA experiments, and obtained survival 
estimates for each that were broadly in line with those published in the original work of Straimer et al. 
describing them. 10 On this basis we can confidently compare RSA survival estimates for our 
transgenic mutant lines back to those obtained for the 3D7 parental line. However, as laboratories 
differ in the duration of 700 nM DHA pulse used, and on methodology for survival readout (flow 
cytometry or microscopy), 18,19 further work on assay standardisation is required before inter-lab 
comparisons of survival estimates will have adequate validity. This is likely to include simple 
normalisation approaches, based on relative survival compared to agreed standard comparators. 
Resistance to artemisinins is unlike that of any other class of antimalarial compounds, being confined 
to the first few hours of intra-erythrocytic development. We and others have now demonstrated this 
phenomenon with mutations in pfk13, 24 pfcoronin, 19 pfap2, and pfubp1 as well as with transient 
pulses of low temperature, 18 suggesting that artemisinin resistance has potentially many genetic and 
environmental origins. In all these cases so far, trophozoites and schizonts are fully sensitive to 
artemisinin. Further, even “resistant” ring-stage parasite forms are still mostly sensitive (e.g. more 
than 70% of parasites are killed by a single 700 nM DHA exposure). It follows that, eventually, even 
mutant parasite populations should be cleared in vivo by extended artemisinin regimens or next-
generation analogues with longer half-lives. 25 This pattern also suggests that there is a particular set 
of cellular processes or circumstances in those first hours of development that are amenable to 
manipulation by mutation, leading to protection from artemisinin’s oxidative mechanism of action. 
Recent studies and our data here suggest that those processes likely involve intracellular traffic and 
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protein turnover – two fundamental aspects of parasite biology. Given the success of artemisinins 
globally, investigations into these mechanisms may reveal other loci capable of manipulating parasite 
artemisinin sensitivity. Potentially some of these may be of relevance to African settings, where K13 
variants have not yet emerged as a cause of treatment failure. Although studies to date in the Mekong 
region have not described any polymorphisms in the pfap2mu locus, this gene has now been identified 
as lying in a region of chromosome 12 showing evidence of recent strong selection in Ghana & 
Malawi.26 Conversely, a mutation in pfubp1 at codon 3138 was found to be associated with P. 
falciparum isolates from Thai malaria patients carrying the C580Y mutation in pfk13, and has thus 
been implicated in slow clearance after artemisinin therapy.21 Given that reduced ring-stage 
artemisinin susceptibility in vitro is now confirmed to have multiple potential origins, tracking the 
phenotypes of delayed parasite clearance and early recrudescence may be more effective than 
surveillance of specific mutations in African P. falciparum populations.   
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Tables  
Table 1.  Comparison of the in vitro susceptibility of pfap2variant transgenic parasite lines with 
parental 3D7 exposed to dihydroartemisinin or other antimalarial drugs for 48 h. 
Compound 
EC50 ± SEM (nM)* 
3D7 
parental 
AP2µS160N 
Clone 1 
AP2µS160N 
Clone 2 
AP2µI591I 
Clone 1 
AP2µI592I 
Clone 2 
AP2µI592T 
Clone 1 
AP2µI592T 
Clone 2 
Chloroquine 13.7 ± 0.3 13.5 ± 0.1 14.9 ± 0.4 11.4 ± 0.8 12.3 ± 0.4 8.7 ± 0.9 7.4 ± 0.3 
Quinine 31.4 ± 2.6 27.7 ± 2.0 32.3 ± 3.3 23.4 ± 2.5 24.0 ± 2.7 24.8 ± 1.9 23.0 ± 2.3 
Piperaquine 31.6 ± 4.5 28.0 ± 3.1 29.6 ± 5.0 23.5 ± 3.6 25.9 ± 0.7 26.5 ± 3.0 22.8 ± 2.5 
Mefloquine 12.2 ± 0.2 12.1 ± 0.5 12.0 ± 0.7 16.8 ± 2.4 17.0 ± 1.4 16.2 ± 1.8 16.0 ± 1.9 
Lumefantrine 30.0 ± 4.0 26.9 ± 2.7 29.6 ± 3.0 30.2 ± 3.0 31.4 ± 2.3 20.9 ± 2.1 21.8 ± 1.0 
Dihydroartemisinin 3.4 ± 0.3 2.9 ± 0.2 2.7 ± 0.7 2.8 ± 0.6 3.1 ± 0.7 3.1 ± 0.7 2.5 ± 0.4 
 
*EC50 values report the mean ± SEM from at least four biological replicates (different cultures, different plates) each 
performed in technical duplicate. Bold face indicates P < 0.01 (Mann-Whitney U test), compared to EC50 estimate for 3D7 
parental line. 
   
 
Table 2.  Comparison of the in vitro susceptibility of pfubp1 variant transgenic parasite lines with 
parental 3D7 exposed to dihydroartemisinin or other antimalarial drugs for 48 h. 
Compound 
EC50 ± SEM (nM)* 
3D7 Parental 
Ubp1V3306F  
clone 1 
UBP1V3306F  
clone 2 
UBP1V3275F  
clone 1 
UBP1V3275F  
clone 2 
Chloroquine 18.8 ± 1.4 13.6 ± 3.0 13.7 ± 2.6 15.3 ± 1.4 14.2 ± 3.0 
Quinine 54.9 ± 12 60.5 ± 15 53.8 ± 15 66.8 ± 21 60.6 ± 17 
Piperaquine 14.9 ± 6.4 9.8 ± 3.5 8.4 ± 0.9 13.4 ± 2.0 11.0 ± 3.2 
Dihydroartemisinin 4.3 ± 0.8 3.3 ± 0.6 3.6 ± 0.6 4.1 ± 0.7 3.8 ± 0.5 
 
*See footnote to Table 1. 
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Figure Legends  
Figure 1.  Gene-editing of pfap2 
A  CRISPR-Cas9 editing was used to install the pfap2muI592T variant codon (red, left) and 
pfap2muS160N variant codon (blue, right) into the endogenous locus. The pictured homologous 
repair constructs were modified to also introduce the I592I wild-type codon in the context of 
silent mutations ablating the Cas9 PAM site, as a control for their impact on phenotype. 
Primers used for genotype mapping anneal outside of the homologous repair template as 
depicted (P1 and P2; Fig. 1, Suppl. Table 1). Recodonised sequence near alternate I592 codons 
(red) also includes a SpeI restriction site, and recodonised sequence near S160 codons (blue) 
ablates an SnaBI restriction site for downstream PCR-RFLP mapping. 
B  Clones of parasite lines expressing AP2µI592T and AP2µI592I (left panel), and AP2µS160N (right 
panel) were generated by limiting dilution and confirmed by PCR-RFLP genotype mapping 
(with SpeI or SnaBI restriction endonuclease) and Sanger sequencing. Amplification of the 
locus with P1 and P2 produces a 2247 bp fragment (Suppl. Table 1); for I592I transgenic 
parasites, SpeI digestion of an amplicon containing the transgenic locus liberates a 301 bp 
fragment. The native amplicon is not cleaved (3D7 lanes). For S160 transgenic parasites, SnaBI 
does not cleave the transgenic amplicon, while wild-type amplicons liberate a 789 bp fragment. 
MW: fragment length in kilobases.   
 
 
Figure 2.  RSA 4h survival estimates for pfap2µ variant transgenic parasite lines (clones 1 and 
2) exposed to artemisinin. 
RSA4 h percent survival of mutant and parental parasite lines compared to untreated control, 
following a 4 h pulse of 700 nM dihydroartemisinin. The Cam3.II-family of parasite lines 
harbour pfk13 mutations as indicated; REV indicates wild-type K13 is encoded.10. Mean of at 
least four biological replicates is shown for each line, each performed in technical duplicate, 
with standard error. Each technical replicate enumerates 100,000 gate-stopping events. P values 
derived from Mann-Whitney U test, comparing each parasite line to 3D7.   
*** P<0.005; NS non-significant;  
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Figure 3.  Gene-editing of pfubp-1   
A. CRISPR-Cas9 editing was used to install the pfubp1Val3275Phe P. falciparum orthologue of the 
previously described P. chabaudi mutation into the endogenous locus in 3D7. The same 
scheme and homology regions were used to install pfubp1Val3306Phe. Installation of either 
mutation introduces a HindIII restriction site, as marked. Primers P3 and P4 (Suppl. Table 1) 
were used to perform PCR-RFLP mapping of transgenic clones. B indicates the position of the 
“Borrmann hotspot” of variation associated with reduced artemisinin susceptibility 13,14  
# indicates position of the Val3306Phe mutation installed using a similarly designed construct.  
Coordinates above the gene are in base-pairs.  
“in. 2” denotes the position of the second intron in the gene. 
B. Clones of parasite lines expressing UBP1Val3275Phe were generated by limiting dilution and 
confirmed by PCR-RFLP genotype mapping (with primers P3 and P4 and HindIII restriction 
digestion) and by Sanger sequencing. Successful integration of the mutant donor template 
introduces a HindIII restriction site.  
C. Clones of parasite lines expressing UBP1Val3306Phe were generated and confirmed as described 
for Val3275Phe mutants.  
 
 
Figure 4.  RSA 4h survival estimates for pfubp1 variant transgenic parasite lines (clones 1 and 
2) exposed to artemisinin.  
RSA survival of mutant and parental parasite lines compared to untreated control, following a 4 
h pulse of 700 nM dihydroartemisinin. Mean of at least four biological replicates is shown for 
each line, each performed in technical duplicate, with standard error. Each technical replicate 
enumerates 100,000 gate-stopping events. P values are derived from the Mann-Whitney U test, 
comparing each parasite line to 3D7.   
*** P<0.005; NS non-significant  
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Suppl. Table 1. Primers used to screen transgenic lines described in this study 
 
 
 
 
 
 
Plasmid Name Purpose 
pUF1-Cas9 Express spCas9 with yDHODH selection cassette 
pL6-AP2µ(I592T)-sgDNA Contains pfap2µ(I592T) donor template, sgRNA expression 
cassette for Cas9 editing, and hDHFR selection cassette 
pL6-AP2µ(I592I)-sgDNA Contains pfap2µ(I592I) donor template, sgRNA expression 
cassette for Cas9 editing, and hDHFR selection cassette 
pL6-AP2µ(S160N)-sgDNA Contains pfap2µ(S160N) donor template, sgRNA expression 
cassette for Cas9 editing, and hDHFR selection cassette 
pL6-Ubp1(V3275F)-sgDNA Contains pfubp1(V3275F) donor template, sgRNA expression 
cassette for Cas9 editing, and hDHFR selection cassette 
pL6-Ubp1(V3306F)-sgDNA Contains pfubp1(V3306F) donor template, sgRNA expression 
cassette for Cas9 editing, and hDHFR selection cassette 
 
Suppl. Table 2. Plasmids used to generate transgenic lines described in this study 
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Supplementary Figure 1. Growth curves for transgenic P. falciparum lines  
A representative clone of 3D7-Ubp1Val3275Phe and one of 3D7-AP2µIle592Thr were grown for 2 
successive intra-erythrocytic development cycles (IDC) and parasitaemia measured, 
compared to the parental 3D7 line. Bars: standard error.   
 
